We are now seeing the potential of a new biochemical treatment option for dementia that addresses the problem of neuroinflammation by blocking the chemicals in the gut that contribute to it's increase. This is a very important shift in thinking that supports the systemic model of what causes dementia and how best to treat the underlying systemic metabolic imbalances. What Quietmind has been doing with the combination of photobiomodulation, neurofeedback and functional medicine is to improve gut dysbiosis by normalizing the photosynthetic nature of how we produce and regulate energy. Near infrared light stimulates mitochondria to produce ATP and regulate the activation of a wide range of chemical processes that directly influence the gut-brain communication process while reducing neuroinflammation, blocking neurotoxin production (Ab42). The new biochemical treatment, sodium oligommerate, will help reduce the inflammatory response in the guy and there by preventing the release of toxic chemicals phenylalanine and isoleucine that are associated with people with mild cognitive impairment and Alzheimer's disease.
We will be following this closely and exploring ways to include this treatment model into our existing protocols.
Click here for description of this important research.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.